Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Pembrolizumab + sEphB4-HSA|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Pembrolizumab||Keytruda||MK-3475||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 62||Keytruda (pembrolizumab) is an antibody against PD-1 that activates T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved in melanoma, SCLC, HNSCC, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, HCC, Merkel cell carcinoma, NMIBC, cutaneous squamous cell carcinoma, MSI-H or dMMR or TMB high advanced solid tumors, PD-L1 expressing NSCLC, gastric and GEJ adenocarcinoma, squamous esophageal carcinoma, and cervical cancer, in combination with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC, with axitinib in RCC, and with Lenvatinib in endometrial carcinoma that is not MSI-H or dMMR (FDA.gov).|
|sEphB4-HSA||EPHB4 Inhibitor 6||sEphB4-HSA is a fusion protein that consists of the extracellular domain of human ephrin type-B receptor 4 (EphB4) and human serum albumin (HSA), which acts as a decoy to inhibit EphB4 signaling, leading to inhibition of tumor cell growth (PMID: 23721559, PMID: 25148033, PMID: 27941840).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03049618||Phase II||Pembrolizumab + sEphB4-HSA||Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475||Recruiting|
|NCT04486781||Phase II||Pembrolizumab + sEphB4-HSA||A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma||Not yet recruiting|
|NCT02717156||Phase II||Pembrolizumab + sEphB4-HSA||Recombinant EphB4-HSA Fusion Protein and Pembrolizumab in Treating Patients With Metastatic or Recurrent Urothelial Cancer That Is Refractory to Certain Chemotherapy Drugs||Recruiting|